Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

ADRB2 Gly16Arg polymorphism, asthma control and lung function decline.

Rebordosa C, Kogevinas M, Guerra S, Castro-Giner F, Jarvis D, Cazzoletti L, Pin I, Siroux V, Wjst M, Antò JM, de Marco R, Estivill X, Corsico AG, Nielsen R, Janson C.

Eur Respir J. 2011 Nov;38(5):1029-35. doi: 10.1183/09031936.00146310. Epub 2011 Mar 24.

2.

Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial.

Wechsler ME, Yawn BP, Fuhlbrigge AL, Pace WD, Pencina MJ, Doros G, Kazani S, Raby BA, Lanzillotti J, Madison S, Israel E; BELT Investigators.

JAMA. 2015 Oct 27;314(16):1720-30. doi: 10.1001/jama.2015.13277.

PMID:
26505596
3.

Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.

Kim SH, Ye YM, Hur GY, Lee HY, Jee YK, Lee SH, Holloway JW, Park HS.

Yonsei Med J. 2009 Apr 30;50(2):182-8. doi: 10.3349/ymj.2009.50.2.182.

4.

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.

Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM.

J Allergy Clin Immunol. 2006 Oct;118(4):809-16. Epub 2006 Aug 28.

PMID:
17030231
5.

Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort.

Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, Koenderman L, Postma DS, Koppelman GH, Maitland-van der Zee AH.

Pharmacogenomics. 2013 Dec;14(16):1965-71. doi: 10.2217/pgs.13.200.

PMID:
24279851
6.

Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis.

Finkelstein Y, Bournissen FG, Hutson JR, Shannon M.

J Asthma. 2009 Nov;46(9):900-5. doi: 10.3109/02770900903199961.

PMID:
19905915
7.

Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.

Giubergia V, Gravina L, Castaños C, Chertkoff L.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):156-60. doi: 10.1016/j.anai.2012.12.018. Epub 2013 Jan 23.

PMID:
23548523
8.

The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma.

Konno S, Hizawa N, Makita H, Shimizu K, Sakamoto T, Kokubu F, Saito T, Endo T, Ninomiya H, Iijima H, Kaneko N, Ito YM, Nishimura M; J-Blossom Study Group.

Pharmacogenet Genomics. 2014 May;24(5):246-55. doi: 10.1097/FPC.0000000000000043.

PMID:
24681963
9.

beta-Adrenergic receptor polymorphisms and response to salmeterol.

Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network.

Am J Respir Crit Care Med. 2006 Mar 1;173(5):519-26. Epub 2005 Dec 1.

10.

Relationship between polymorphisms in the 5' leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China.

Fu WP, Zhao ZH, Zhong L, Sun C, Fang LZ, Liu L, Zhang JQ, Wang L, Shu JK, Wang XM, Dai LM.

Respirology. 2011 Nov;16(8):1221-7. doi: 10.1111/j.1440-1843.2011.02028.x.

PMID:
21801278
11.

Is Gly16Arg β2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?

Jabbal S, Manoharan A, Lipworth J, Anderson W, Short P, Lipworth B.

Lung. 2016 Apr;194(2):267-71. doi: 10.1007/s00408-016-9848-5. Epub 2016 Feb 15.

12.

Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma.

Slankard M, Michelis MA, Mansukhani M, McGoey B, Paige A, Andrews H, Lederer D, Canfield S, DiMango E.

J Asthma. 2016 Oct;53(8):783-9. doi: 10.3109/02770903.2016.1161049. Epub 2016 Apr 6.

PMID:
27050801
13.

Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response.

Ambrose HJ, Lawrance RM, Cresswell CJ, Goldman M, Meyers DA, Bleecker ER.

Respir Res. 2012 May 4;13:37. doi: 10.1186/1465-9921-13-37.

14.
15.

Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.

Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW, Castro M, Chardon D, Erzurum SC, Israel E, Montealegre F, Wenzel SE, Peters SP, Meyers DA, Bleecker ER.

Lancet Respir Med. 2014 Mar;2(3):204-13. doi: 10.1016/S2213-2600(13)70289-3. Epub 2014 Jan 27.

16.

The emerging role of tiotropium for patients with asthma.

Bollmeier SG, Lee SY.

Ann Pharmacother. 2013 May;47(5):704-13. doi: 10.1345/aph.1R641. Epub 2013 Apr 23. Review.

PMID:
23613100
17.

Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.

Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HG.

Am J Respir Crit Care Med. 2010 Apr 1;181(7):676-87. doi: 10.1164/200809-1511OC. Epub 2009 Nov 12.

PMID:
19910613
18.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM.

J Allergy Clin Immunol. 2011 Aug;128(2):315-22. doi: 10.1016/j.jaci.2011.06.004.

PMID:
21807250
19.

Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment.

Turner S, Francis B, Vijverberg S, Pino-Yanes M, Maitland-van der Zee AH, Basu K, Bignell L, Mukhopadhyay S, Tavendale R, Palmer C, Hawcutt D, Pirmohamed M, Burchard EG, Lipworth B; Pharmacogenomics in Childhood Asthma Consortium.

J Allergy Clin Immunol. 2016 Jul;138(1):107-113.e5. doi: 10.1016/j.jaci.2015.10.045. Epub 2016 Jan 7.

20.

Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.

Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM.

Curr Med Res Opin. 2009 Sep;25(9):2251-8. doi: 10.1185/03007990903155915.

PMID:
19622006

Supplemental Content

Support Center